Compare TTEK & RGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TTEK | RGEN |
|---|---|---|
| Founded | 1966 | 1981 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.6B | 8.2B |
| IPO Year | 1991 | N/A |
| Metric | TTEK | RGEN |
|---|---|---|
| Price | $34.23 | $165.14 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 10 |
| Target Price | $43.25 | ★ $170.90 |
| AVG Volume (30 Days) | ★ 3.2M | 826.7K |
| Earning Date | 11-12-2025 | 10-28-2025 |
| Dividend Yield | ★ 0.76% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.93 | 0.03 |
| Revenue | ★ $4,617,360,000.00 | $707,890,000.00 |
| Revenue This Year | N/A | $17.84 |
| Revenue Next Year | $6.70 | $12.57 |
| P/E Ratio | ★ $36.71 | $5,343.41 |
| Revenue Growth | 6.84 | ★ 11.74 |
| 52 Week Low | $27.27 | $102.97 |
| 52 Week High | $43.50 | $182.52 |
| Indicator | TTEK | RGEN |
|---|---|---|
| Relative Strength Index (RSI) | 49.74 | 58.40 |
| Support Level | $34.13 | $161.67 |
| Resistance Level | $35.60 | $170.40 |
| Average True Range (ATR) | 0.94 | 5.85 |
| MACD | 0.01 | 0.09 |
| Stochastic Oscillator | 43.31 | 67.15 |
Tetra Tech Inc provides consulting and engineering services for environmental, infrastructure, resource management, energy, and international development markets. It specializes in providing water-related services for public and private clients. It designs infrastructure, facilities, and other structures with complex plans and resource management. it has two reportable segments. Its Government Services Group (GSG) segment includes activities with U.S. government clients (federal, state and local) and activities with development agencies world-wide. Commercial/International Services Group (CIG) segment, which derives maximum revenue, includes activities with U.S. commercial clients and international clients other than development agencies.
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.